Analyst Expectations For Vertex Pharmaceuticals's Future
Portfolio Pulse from Benzinga Insights
Analysts have provided diverse evaluations for Vertex Pharmaceuticals (NASDAQ:VRTX) over the past three months, with a mix of bullish, somewhat bullish, indifferent, and bearish ratings. The average 12-month price target has increased by 1.68% to $452.9. Key analysts have adjusted their ratings and price targets, reflecting their evolving perspectives on the company's performance.
May 31, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have mixed ratings for Vertex Pharmaceuticals, with a recent increase in the average 12-month price target to $452.9. Key analysts have adjusted their ratings and price targets, indicating a positive shift in sentiment.
The increase in the average 12-month price target and the adjustments in ratings by key analysts suggest a positive short-term outlook for Vertex Pharmaceuticals. The diverse range of ratings indicates varying levels of confidence among analysts, but the overall trend is upward.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100